LB-0702
Hematology pathologies
Pre-clinicalActive
Key Facts
About Syna Therapeutics
Syna Therapeutics is a Barcelona-based joint venture between pharmaceutical manufacturer Reig Jofre and biotech developer LeanBio, established to capitalize on the global biosimilars market. The company combines LeanBio's R&D platforms with Reig Jofre's industrial-scale manufacturing capabilities for injectable and lyophilized products. A key milestone is an exclusive global licensing agreement with Intas Pharmaceuticals for its lead hematology biosimilar, LB-0702, with clinical trials slated for 2023. Syna's strategy is to develop a pipeline of biosimilars aimed at reducing healthcare costs while treating serious chronic illnesses.
View full company profile